AVIR Q3 2021 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$484M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M

Gross Profit

-$10M-31.1% margin

Operating Income

-$22M-67.5% margin

Net Income

-$28M-85.9% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-45.7%

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$23M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$844M

Total Liabilities

$262M

Stockholders' Equity

$581M

Cash & Equivalents

$840M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$0	—
Gross Profit	-$10M	-$14M	+24.9%
Operating Income	-$22M	-$18M	-25.6%
Net Income	-$28M	-$18M	-60.0%